Pacira BioSciences PCRX 深 沪
等待开盘 08-14 09:30:00 美东时间
23.63
-0.070
-0.30%
华盛通- 最 高24.285
- 今 开24.08
- 成交量 9.42万股
- 最 低 23.63
- 昨 收 23.70
- 总市值 9.42亿
- 52周最高 27.66
- 市盈率 静 151.28
- 换手率 0.24%
- 52周最低 18.80
- 委 比 18.11%
- 总股本 3986.19万
- 历史最高 121.95
- 量 比 0.32
- 振 幅 2.76%
- 历史最低 6.51
- 每 手 1
- 风险率 1.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to five new employees under its 2014 Inducement Plan. Two employees received stock options for 8,500 shares, and five received restricted stock units for 14,200 shares. The stock options have a 10-year term, a four-year vesting schedule, and an exercise price of $27.62 per share. Restricted stock units vest annually over four years. Pacira, a leader in non-opioid pain therapies, offers products like EX...
08-07 12:00
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 sales results.
Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 sales results.
08-06 01:41
Pacira BioSciences shares are trading lower after the company lowered its FY2026 sales guidance.
Pacira BioSciences shares are trading lower after the company lowered its FY2026 sales guidance.
08-06 01:40
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.
08-05 19:47
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
08-05 04:03
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $192.400 milli...
08-05 04:02
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will release its second quarter 2026 financial results after U.S. markets close on August 4, 2026. A live conference call and webcast will follow at 4:30 p.m. ET. Listeners can pre-register for the call or access the webcast via investor.pacira.com. A replay will be available for approximately two weeks. Pacira specializes in non-opioid pain therapies, offering products like EXPAREL®, ZILRETTA®...
07-22 12:00
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.
07-01 20:15
